Clinical Trial Update: A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating BMS-986012 in combination with carboplatin, etoposide, and nivolumab as first-line therapy for extensive-stage small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• BMS-986012
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING